2733573-94-7
Chemical Structure
Zovegalisib
Synonym(s): RLY-2608
- CAS No.: 2733573-94-7
- Formula:C29H14ClF5N6O2
- Molecular Weight:608.91
IUPAC Name: (R)-N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide
InChIKey: VYWRYBZVVSPTQN-SANMLTNESA-N
SMILES: O=C1N[C@@H](C2=CC(F)=CC=C2Cl)C(C1=C3)=C(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)C=C3C5=C(C#N)N6C(C=C5)=NC=N6
Biological Activity: Zovegalisib (RLY-2608) is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity. Zovegalisib inhibits tumor growth in PIK3CA-mutant xenograft mice models with minimal impact on insulin[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zovegalisib | 99.79% | Zovegalisib (RLY-2608) is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity. Zovegalisib inhibits tumor growth in PIK3CA-mutant xenograft mice models with minimal impact on insulin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-153306A(S)-Zovegalisib -
Similarity Score 0.71
HY-160458PI3Kα-IN-17 -
Similarity Score 0.60
HY-182946PI3Kα-IN-31 -
Similarity Score 0.48
HY-164529SJ-C1044 -
Similarity Score 0.47
HY-178951STING-IN-17 -
Similarity Score 0.46
HY-16025EOC317 -
Similarity Score 0.46
HY-18911Type-II-IN-1 -
Similarity Score 0.46
HY-171131BTK-IN-41 -
Similarity Score 0.46
HY-178042SS-3091 -
Explore the MedChemAI to find more analogs
References
- [1]. Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2. [Content Brief]
- [2]. Pazolli E, et al. RLY-2608: the first allosteric mutant-and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models[J]. Cancer Res., 2022, 82.
- [3]. Perez C A, et al. First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer[J]. 2022.
